EyeYon Medical Receives CE Mark for its EndoArt® Implant to Treat Chronic Corneal Edema Font : A-A+
EndoArt® previously received Innovative Device Status by the Chinese NMPA, and Breakthrough Device Designation from the US Food and Drug Administration TEL AVIV, Israel, June 8, 2021 /PRNewswire/ EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announced today that it has received CE Mark for its EndoArt®, after clinical trials demonstrated safety and efficacy for treating chronic corneal edema. The CE Mark serves as approval by the European Union (EU) to commercialize EndoArt®, the world s first and only synthetic implant, which replaces the human endothelium that the human body can never regenerate. The current standard of care involves corneal transplantation of human tissue. This unique implant enables doctors to treat endothelial-related chronic corneal edema with a minimally invasive surger
DACADOO AND DIG ANNOUNCE PARTNERSHIP IN LIFESTYLE INSURANCE
Swiss health tech and insurtech company, dacadoo and Amsterdam-based Digital Insurance Group (DIG) are partnering up to expand their set of insurtech solutions for banking, insurance and brokers.
Using a new quote & buy products set to improve the underwriting process for life operators, the partnership aims to establish real-time pricing of life insurance in the major continents where both companies already have a presence in.
Ingo Weber, CEO & co-founder of DIG said: “Our mission is to give more people access to insurance and make sure they get the protection they need for themselves and their families. We work a lot with innovative insurers and enable them to build disruptive distribution and engagement models including ecosystems. With the solution we’re now building with dacadoo we can even increase the level of personalisation and customer experience.”
EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt In China
TEL-AVIV, Israel, April 7, 2021 /PRNewswire/ EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announces today that EndoArt was granted the Innovative Device Status by China s Center for Medical Device Evaluation, the arm of the National Medical Products Administration (NMPA). Following the announcement, the EndoArt became the only ophthalmic device in the world to receive both China s Innovative Device Status and the Breakthrough Device Designation from the U.S. Food and Drug Administration.
The EndoArt is the world s first synthetic implant that enables doctors to treat chronic corneal edema, the main reason for the world s most common organ transplant, with a minimally invasive surgery that erodes the use of human tissue.The EndoArt is designed to replace dysfunctional endothelium in patients awaiting human donor t
Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation
Study Will Determine the Safety and Effectiveness of Pulsed Electrical Fields to Interrupt Irregular Heart Rhythms Medtronic plc the global leader in medical technology, today announced the first procedures in the investigational device exemption pivotal trial to evaluate the PulseSelect ™ Pulsed Field Ablation System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation . … Study Will Determine the Safety and Effectiveness of Pulsed Electrical Fields to Interrupt Irregular Heart Rhythms
Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect ™ Pulsed Field Ablation (PFA) System, a novel, breakthrough technology that uses pulsed electric fields to treat atrial fibrillation (A